Profile data is unavailable for this security.
About the company
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Its HIF-based product candidates and other pipeline assets are being evaluated to target areas of unmet needs. Its product candidates include AKB-9090, AKB-10108, AKB-097 and praliciguat.
- Revenue in USD (TTM)225.07m
- Net income in USD-15.91m
- Incorporated2007
- Employees181.00
- LocationAkebia Therapeutics Inc245 First StreetCAMBRIDGE 02142United StatesUSA
- Phone+1 (617) 871-2098
- Fax+1 (617) 871-2099
- Websitehttps://akebia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Journey Medical Corp | 59.40m | -8.66m | 210.69m | 41.00 | -- | 7.87 | -- | 3.55 | -0.3645 | -0.3645 | 2.58 | 0.982 | 0.796 | 1.79 | 4.15 | 1,448,756.00 | -11.61 | -22.37 | -22.74 | -50.55 | 64.40 | 59.45 | -14.58 | -27.43 | 1.12 | -3.30 | 0.4928 | -- | -29.11 | 9.96 | -280.79 | -- | 44.27 | -- |
| Mediwound Ltd | 20.93m | -20.60m | 221.66m | 111.00 | -- | 4.41 | -- | 10.59 | -1.90 | -1.90 | 1.93 | 3.91 | 0.2475 | 4.59 | 3.69 | 188,576.60 | -24.36 | -35.38 | -35.12 | -48.39 | 18.53 | 32.18 | -98.43 | -71.55 | 2.48 | -- | 0.1416 | -- | 8.22 | -8.65 | -350.03 | -- | 51.27 | -- |
| Opus Genetics Inc | 14.63m | -68.20m | 251.03m | 18.00 | -- | 39.37 | -- | 17.16 | -1.76 | -1.76 | 0.2952 | 0.0925 | 0.3825 | -- | 3.85 | 812,944.40 | -178.28 | -76.30 | -330.00 | -86.90 | -- | -- | -466.09 | -185.79 | -- | -- | 0.1518 | -- | -42.30 | -- | -476.13 | -- | -- | -- |
| Lifecore Biomedical Inc | -100.00bn | -100.00bn | 265.26m | 406.00 | -- | -- | -- | -- | -- | -- | -- | 0.9818 | -- | -- | -- | -- | -- | -7.91 | -- | -10.85 | -- | 32.86 | -- | -23.15 | 1.67 | -- | 0.787 | -- | 0.4725 | -4.24 | -575.39 | -- | -12.85 | -- |
| Abeona Therapeutics Inc | 400.00k | 82.35m | 271.50m | 136.00 | 4.53 | 1.53 | 3.21 | 678.75 | 1.11 | 1.11 | 0.0073 | 3.27 | 0.0023 | -- | 0.2478 | 2,941.18 | 46.83 | -62.23 | 52.94 | -78.23 | -122.00 | -- | 20,587.50 | -1,824.21 | 9.53 | -- | 0.1034 | -- | -100.00 | -- | -17.62 | -- | -17.78 | -- |
| Evolus Inc | 285.82m | -58.56m | 278.73m | 329.00 | -- | -- | -- | 0.9752 | -0.9125 | -0.9125 | 4.46 | -0.4441 | 1.27 | 4.09 | 6.01 | 860,912.60 | -26.11 | -37.04 | -36.48 | -57.14 | 65.83 | 65.19 | -20.49 | -51.26 | 1.53 | -2.13 | 1.25 | -- | 31.76 | 50.12 | 18.26 | -- | 1.10 | -- |
| Fennec Pharmaceuticals Inc | 38.79m | -6.94m | 287.57m | 36.00 | -- | -- | -- | 7.41 | -0.2524 | -0.2524 | 1.41 | -0.1601 | 0.7171 | 1.48 | 2.41 | -- | -12.83 | -55.15 | -15.26 | -64.98 | 93.12 | -- | -17.89 | -107.31 | 4.44 | -2.44 | 1.33 | -- | 123.69 | -- | 97.28 | -- | -- | -- |
| X4 Pharmaceuticals Inc | 33.98m | -95.10m | 298.16m | 143.00 | -- | 1.39 | -- | 8.77 | -10.50 | -10.50 | 2.94 | 2.45 | 0.1989 | 1.75 | 25.37 | 237,615.40 | -55.66 | -55.04 | -65.82 | -63.45 | 83.24 | -- | -279.86 | -6,897.81 | 5.48 | -19.26 | 0.5525 | -- | -- | -- | 62.98 | -- | 111.28 | -- |
| AC Immune SA | 5.70m | -93.66m | 300.23m | 133.00 | -- | 3.69 | -- | 52.70 | -0.932 | -0.932 | 0.0567 | 0.8104 | 0.021 | -- | 0.3392 | 42,835.79 | -34.57 | -27.41 | -66.37 | -30.60 | -- | -- | -1,643.94 | -505.58 | -- | -- | 0.0695 | -- | 84.51 | -24.38 | 6.12 | -- | -21.11 | -- |
| Akebia Therapeutics Inc | 225.07m | -15.91m | 321.09m | 181.00 | -- | 7.72 | -- | 1.43 | -0.0761 | -0.0761 | 0.8951 | 0.1568 | 0.7879 | 2.08 | 4.57 | 1,243,486.00 | -5.57 | -38.92 | -8.55 | -61.07 | 81.89 | 71.93 | -7.07 | -76.49 | 1.80 | 0.7147 | 0.8219 | -- | -17.70 | -13.72 | -33.67 | -- | -65.40 | -- |
| Puma Biotechnology Inc | 212.00m | 36.98m | 343.67m | 172.00 | 9.20 | 2.98 | 7.14 | 1.62 | 0.7414 | 0.7414 | 4.23 | 2.29 | 1.00 | 8.06 | 4.81 | 1,232,529.00 | 17.46 | -3.25 | 32.09 | -5.70 | 76.91 | 75.67 | 17.44 | -3.18 | 1.62 | 8.84 | 0.2263 | -- | -2.19 | -3.28 | 40.23 | -- | -28.80 | -- |
| Enanta Pharmaceuticals Inc | 66.98m | -71.54m | 401.92m | 120.00 | -- | 3.17 | -- | 6.00 | -3.20 | -3.20 | 2.89 | 4.36 | 0.1975 | -- | 8.26 | 558,166.70 | -21.10 | -26.15 | -24.48 | -29.36 | -- | -- | -106.80 | -134.68 | -- | -- | 0.5181 | -- | -3.42 | -11.81 | 29.43 | -- | 54.92 | -- |
Data as of Feb 13 2026. Currency figures normalised to Akebia Therapeutics Inc's reporting currency: US Dollar USD
25.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2025 | 16.72m | 6.30% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 13.99m | 5.27% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 11.84m | 4.46% |
| Geode Capital Management LLCas of 30 Sep 2025 | 6.18m | 2.33% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 3.95m | 1.49% |
| Foord Asset Management (Singapore) Pte Ltd.as of 30 Jun 2025 | 3.82m | 1.44% |
| Morgan Stanley & Co. LLCas of 30 Sep 2025 | 3.49m | 1.32% |
| Qube Research & Technologies Ltd.as of 30 Sep 2025 | 3.21m | 1.21% |
| Millennium Management LLCas of 30 Sep 2025 | 2.86m | 1.08% |
| Franklin Advisers, Inc.as of 30 Sep 2025 | 2.68m | 1.01% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
